Literature DB >> 22132017

Oncologic Angiogenesis Imaging in the clinic---how and why.

Karen A Kurdziel, Liza Lindenberg, Peter L Choyke.   

Abstract

The ability to control the growth of new blood vessels would be an extraordinary therapeutic tool for many disease processes. Too often, the promises of discoveries in the basic science arena fail to translate to clinical success. While several anti angiogenic therapeutics are now FDA approved, the envisioned clinical benefits have yet to be seen. The ability to clinically non-invasively image angiogenesis would potentially be used to identify patients who may benefit from anti-angiogenic treatments, prognostication/risk stratification and therapy monitoring. This article reviews the current and future prospects of implementing angiogenesis imaging in the clinic.

Entities:  

Year:  2011        PMID: 22132017      PMCID: PMC3224985          DOI: 10.2217/iim.11.31

Source DB:  PubMed          Journal:  Imaging Med        ISSN: 1755-5191


  68 in total

1.  Detectability of small blood vessels with high-frequency power Doppler and selection of wall filter cut-off velocity for microvascular imaging.

Authors:  Stephen Z Pinter; James C Lacefield
Journal:  Ultrasound Med Biol       Date:  2009-04-25       Impact factor: 2.998

2.  Isolation of the human platelet glycoprotein IIb gene and characterization of the 5' flanking region.

Authors:  M H Prandini; E Denarier; P Frachet; G Uzan; G Marguerie
Journal:  Biochem Biophys Res Commun       Date:  1988-10-14       Impact factor: 3.575

Review 3.  VEGF: an update on biological and therapeutic aspects.

Authors:  N Ferrara
Journal:  Curr Opin Biotechnol       Date:  2000-12       Impact factor: 9.740

4.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.

Authors:  Peter M Smith-Jones; David Solit; Farzana Afroze; Neal Rosen; Steven M Larson
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

5.  Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a.

Authors:  C W White; H M Sondheimer; E C Crouch; H Wilson; L L Fan
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

6.  89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

Authors:  Wouter B Nagengast; Maarten A de Korte; Thijs H Oude Munnink; Hetty Timmer-Bosscha; Wifred F den Dunnen; Harry Hollema; Johan R de Jong; Michael R Jensen; Cornelia Quadt; Carlos Garcia-Echeverria; Guus A M S van Dongen; Marjolijn N Lub-de Hooge; Carolien P Schröder; Elisabeth G E de Vries
Journal:  J Nucl Med       Date:  2010-04-15       Impact factor: 10.057

7.  VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.

Authors:  Wouter B Nagengast; Marjolijn N Lub-de Hooge; Sjoukje F Oosting; Wilfred F A den Dunnen; Frank-Jan Warnders; Adrienne H Brouwers; Johan R de Jong; Patricia M Price; Harry Hollema; Geke A P Hospers; Philip H Elsinga; Jan Willem Hesselink; Jourik A Gietema; Elisabeth G E de Vries
Journal:  Cancer Res       Date:  2010-11-17       Impact factor: 12.701

Review 8.  Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.

Authors:  Robert J Ignoffo
Journal:  Am J Health Syst Pharm       Date:  2004-11-01       Impact factor: 2.637

9.  Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography.

Authors:  Jürgen K Willmann; Kai Chen; Hui Wang; Ramasamy Paulmurugan; Mark Rollins; Weibo Cai; David S Wang; Ian Y Chen; Olivier Gheysens; Martin Rodriguez-Porcel; Xiaoyuan Chen; Sanjiv S Gambhir
Journal:  Circulation       Date:  2008-02-04       Impact factor: 29.690

10.  Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.

Authors:  Shivaani Kummar; Martin E Gutierrez; Alice Chen; Ismail B Turkbey; Deborah Allen; Yvonne R Horneffer; Lamin Juwara; Liang Cao; Yunkai Yu; Yeong Sang Kim; Jane Trepel; Helen Chen; Peter Choyke; Giovanni Melillo; Anthony J Murgo; Jerry Collins; James H Doroshow
Journal:  Eur J Cancer       Date:  2011-01-17       Impact factor: 9.162

View more
  6 in total

1.  The Distribution Volume of 18F-Albumin as a Potential Biomarker of Antiangiogenic Treatment Efficacy.

Authors:  Jyoti Roy; Frank Kuo; Falguni Basuli; Mark R Williams; Karen Wong; Michael V Green; Jurgen Seidel; Stephen S Adler; Biying Xu; Peter L Choyke; Elaine M Jagoda
Journal:  Cancer Biother Radiopharm       Date:  2019-02-15       Impact factor: 3.099

2.  First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.

Authors:  Richard P Baum; Harshad R Kulkarni; Dirk Müller; Stanley Satz; Narasimhan Danthi; Young-Seung Kim; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2015-05       Impact factor: 3.099

Review 3.  In vivo imaging of therapy-induced anti-cancer immune responses in humans.

Authors:  Erik H J G Aarntzen; Mangala Srinivas; Caius G Radu; Cornelis J A Punt; Otto C Boerman; Carl G Figdor; Wim J G Oyen; I Jolanda M de Vries
Journal:  Cell Mol Life Sci       Date:  2012-10-05       Impact factor: 9.261

4.  Immuno-PET imaging of tumor endothelial marker 8 (TEM8).

Authors:  Frank Kuo; Stephanie Histed; Biying Xu; Veerendra Bhadrasetty; Lawrence P Szajek; Mark R Williams; Karen Wong; Haitao Wu; Kelly Lane; Vincent Coble; Olga Vasalatiy; Gary L Griffiths; Chang H Paik; Osama Elbuluk; Christopher Szot; Amit Chaudhary; Brad St Croix; Peter Choyke; Elaine M Jagoda
Journal:  Mol Pharm       Date:  2014-07-11       Impact factor: 4.939

5.  Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.

Authors:  Yi-Fang Chen; Ang Yuan; Kuan-Hung Cho; Yi-Chien Lu; Mark Yen-Ping Kuo; Jyh-Horng Chen; Yeun-Chung Chang
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

6.  Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.

Authors:  Kewei Zhao; Chunsheng Wang; Fang Shi; Yong Huang; Li Ma; Minghuan Li; Yipeng Song
Journal:  BMC Cancer       Date:  2021-01-14       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.